Baystreet Staff - Tuesday, August 22, 2023 Marvel Biosciences Corp 09:50 AM EST - Marvel Biosciences Corp : Announces that it has successfully completed its 4-week good laboratory practice, FDA investigational new drug, dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. Marvel Biosciences Corp shares V.MRVL are trading up one cent at $0.08. Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=MRVL%3ACA&qmodStoryID=6725144481333502